T he metabolic syndrome comprises a cluster of risk factors, including obesity, insulin resistance, hepatic steatosis, and dyslipidemia. It is associated with a variety of cardiovascular diseases such as atherosclerosis, myocardial infarction, and stroke.
accompanies this cluster. 2, 3 Considerable evidence implicates the adaptive immune system in the regulation of adipose tissue inflammation and glucose homeostasis. Immune effector cells modulate inflammatory and metabolic cascades throughout all stages of obesity. T cells, B cells, macrophages, and mast cells infiltrate VAT and orchestrate local and systemic inflammatory responses by interacting with each other and with resident adipocytes. [4] [5] [6] CD4 + T-helper (Th) cells, CD4 + T-regulatory (T reg ) cells, CD8 + T cells, and related chemokines and cytokines such as RANTES (regulated on activation normal T cell expressed and secreted) and interferon-γ (IFNγ) colocalize within the inflammatory cell compartment in adipose tissue. 7 In lean adipose tissue, the vast majority of T lymphocytes share features of anti-inflammatory, interleukin (IL)-13-, IL-4-, and IL-10-secreting Th2 or T reg cells. 8 In obesity, proinflammatory Th1 cells expressing IFNγ overwhelm Th2 cells. 9 Th1 cells, in turn, activate proinflammatory cytokine-secreting macrophages and promote their conversion from M2-like, IL-10-secreting, alternatively activated macrophages to classically activated, M1-like macrophages. 10, 11 Despite description of the kinetics of cellular infiltration and the associated cytokine/chemokine profiles during the development of obesity, the underlying cause modulating T-cell polarization in adipose tissue inflammation remains poorly understood. Activation and differentiation of T cells require costimulatory signaling. 12 The costimulatory molecule CD40, a member of the tumor necrosis factor (TNF) receptor superfamily, critically regulates B-cell and T-cell function in adaptive immunity and inflammation by interacting with CD40L (CD154). 13, 14 We and others recently showed that preadipocytes and adipocytes express CD40 and proposed that adipose tissue inflammation requires CD40L action. [15] [16] [17] In contrast, Guo et al 18 recently demonstrated that mice with a genetic deficiency of the CD40 receptor exhibited a hyperinflammatory phenotype in a model of diet-induced obesity (DIO), suggesting that CD40 surprisingly plays a protective role in the metabolic syndrome. In light of the proposed proinflammatory role of CD40 in various disease models, the findings of Guo et al raise interesting questions about the exact molecular mechanism, the cellular origin of the CD40 phenotype, and whether CD40 might be responsive to therapeutic stimulation. Here, we aim to address these questions and to further investigate and confirm the effects of CD40 on metabolic and inflammatory phenotype.
Methods
An expanded Methods section is available in the online-only Data Supplement.
Animal Protocols
Male CD40 −/− mice (B6.129P2-Cd40tm1Kik/J, Jackson Laboratories) on a C57BL/6J background (approximate) and aged-matched wildtype C57BL/6J (WT) mice consumed a high-fat diet (HFD) or a low-fat diet (LFD) ad libitum for 20 weeks. As indicated, male WT mice were injected 3 times per week (100 μg IP) with the agonistic anti-CD40 antibody FGK45 (Miltenyi, Germany) or an isotype control and were pair-fed with HFD for 6 weeks. After bone marrow transplantations or adoptive transfers of T cells, animals were pairfed with HFD as indicated. All experimental protocols were approved by the animal ethics committee of the Alfred Medical Research and Education Precinct, Melbourne, Australia, and the animal ethics committee at the University of Freiburg, Freiburg, Germany. All procedures were carried out in accordance with institutional guidelines.
Bone Marrow Transplantation
Recipient mice were lethally irradiated with 1 dose of 700 cGy (Gammacell Exactor 40) . Bone marrow of donor animals was filtered, washed, and injected at a concentration of 1×10 7 cells into the tail vein.
Adoptive Transfer of T Cells
Splenic T cells from WT or CD40 −/− mice were isolated by negative cell separation (Stem Cell Technologies). Purity was >95% in flow cytometry. Then, 5×10 6 cells were transferred into Rag-1 −/− mice by intraperitoneal injection. Donor animals subsequently consumed HFD for 8 weeks.
Body Composition Analysis
Body composition was assessed by EchoMRI (Echo Medical Systems).
Metabolic Caging
Animals were allowed to acclimatize to metabolic cages (Oxymax/ CLAMS, Columbus Instruments) before the observation period. Food intake, ambulatory movement, heat production, O 2 consumption, and CO 2 production were assessed and recorded during a 24-hour observation period.
Intraperitoneal Glucose Tolerance Testing and Insulin Tolerance Testing
Mice were starved 6 hours before the procedures and received intraperitoneal glucose injections (0.25-1 g/kg lean body mass) for glucose tolerance testing. For insulin tolerance testing, mice were injected intraperitoneally with insulin (0.1-0.5 U/kg).
Preparation of the Stromal Vascular Fraction
Murine epididymidal fat pads were minced and digested with collagenase B (0.5 mg/mL). Digested tissue was filtered through nylon mesh (100 μm). The stromal vascular fraction (SVF) and adipocyte fraction were obtained from the resulting pellet and supernatant, respectively.
Flow Cytometry
Cells were washed in PBS; Fc receptors were blocked by anti-CD16/ CD32; and cells were labeled with the indicated antibodies (all from eBioscience) before quantification with a flow cytometer (BD FACS Canto II, BD Biosciences). Leukocyte 
Isolation of Total RNA and Quantitative Real-Time Polymerase Chain Reaction
Isolation of RNA and quantitative polymerase chain reaction were performed as previously described. 16 Alternatively, RNA samples were screened with a MouseWG-6 v2 Expression BeadChip (Illumina).
Quantification of Intracellular Cytokines
Intracellular proteins were quantified by flow cytometry in splenocytes or cells of the SVF. Cells were restimulated by phorbol-myristateacetate (81nmol/L), ionomycin (1.34 μmol/L), and brefeldin A (10 μmol/L) in RPMI for 15 hours or by cultivation on mouse anti-CD3-coated cell culture plates for the indicated time.
Measurement of Antibody Titers
Plasma titers of antibodies were determined by chemiluminescent ELISA, as previously described. 16 
Clinical Study
In the observational study, a total of 183 patients visiting the Cardiovascular Risk Area of the University Clinic of Navarra (Spain) for a routine assessment were included in the study. Exclusion criteria included apparent atherosclerotic disease based on the absence of history of coronary disease, stroke, or peripheral artery disease and a normal ECG; impaired renal or liver function; arteritis; connective tissue diseases; inflammatory disease; or cancer. Sample size was calculated according to the results of a previous study performed in our laboratory. Sample size was estimated with the EPIDAT program version 3.1 to detect differences of 0.2 ng/mL in soluble CD40L, with a statistical power of 90%. The local committee on human research approved the study, which was performed in accordance with the Declaration of Helsinki, and all participants gave written informed consent. All participants underwent a complete medical examination, and anthropometric measurements were taken. Blood pressure was measured with a mercury sphygmomanometer in a sitting position. The average of 2 measurements was considered. Subjects were classified as obese and nonobese according to body mass index (obese, ≥27.5 kg/m 2 ). High waist circumference was defined as >88 cm for women and >102 cm for men. Serum and plasma were collected in Vacutainer tubes. Fasting serum glucose, cholesterol, triglycerides, and high-density lipoprotein cholesterol were measured by standard laboratory techniques. Plasma C-reactive protein levels were measured by immunoturbidimetry in a Roche Modular analyzer. Soluble CD40 (sCD40) in plasma was determined by ELISA (R&D Systems). Subcutaneous fat tissue samples were obtained from ZenBio.
Statistical Analysis
Results from the data analysis in the text are presented as mean±SD. Statistical testing used the Student unpaired t test between groups as indicated. Significances in glucose tolerance testing and insulin tolerance testing were assessed by repeated-measures 2-way ANOVA between treatment groups. In the clinical study, the normal distribution of variables was tested with the Shapiro-Wilk test. Differences across groups were compared by ANOVA, followed by the Bonferroni post hoc test for normal variables and the Kruskal-Wallis test for nonnormal variables. Spearman correlation coefficients for continuous variables were also used to assess univariate correlations. Values of P<0.05 were considered statistically significant. Statistical analysis was performed with SPSS (SPSS Inc).
Results

CD40 Is Preferably Expressed by Adipocytes From Obese Adipose Tissue
To test whether CD40 is regulated during the metabolic syndrome, we quantified levels of sCD40 in plasma of male C57BL6 mice consuming HFD (45% kcal/fat) or LFD for 20 weeks. Interestingly, sCD40 increased with HFD (133.1±19.6 versus 234.9±122.9 pg/mL; n ≥12 per group; P=0.025; Figure 1A ). Accordingly, in VAT lysates, we detected a 137±74.5% increase in CD40 mRNA expression in mice fed HFD (0.002±0.0015 versus 0.005±0.002 copy numbers per GAPDH; n=8 per group; P=0.007; Figure 1B Figure 1C and 1D) , as previously suggested. 17 Within the SVF, CD8 + T cells, proinflammatory M1-like macrophages, and endothelial cells expressed the highest levels of CD40 ( Figure 1E) Figure 1F ) and to a modest degree on circulating CD8
+ T cells compared with lean animals (a reduction of 9.7±5.4%; n=8 per group; P<0.01; Figure 1G ), suggesting hampered effector function of T-cell CD40 in obesity. Figure 2C ). In accord, plasma levels of the adipokine leptin were higher in CD40-deficient mice (2.8±1.1 versus 5.3±1.7 pg/mL; n ≥9 per group; P=0.001; Figure 2D ). CD40 deficiency altered the properties of basic energy metabolism such as heat production, respiratory quotient, and food intake ( Figure I in the online-only Data Supplement). Despite equal changes in basic energy metabolism, CD40-deficient animals consuming LFD gained less weight (Figures II and III in the online-only Data Supplement), suggesting that increased weight gain was diet dependent. CD40 −/− mice on HFD showed impaired glucose tolerance (n ≥6 per group; P=0.0136 in repeated measures 2-way ANOVA; Figure 2E ) and insulin resistance (n ≥6 per group; P<0.0001 in repeated 2-way ANOVA; Figure 2F ). Likewise, fasting glucose levels were elevated in CD40 −/− mice by 21.8±23.3% (n ≥14 per group; P=0.009; Figure 2G ). Interestingly, insulin levels in CD40 −/− mice were lower before and during an intraperitoneal glucose tolerance testing ( Figure IV Obesity is associated with hepatic steatosis. 19 Although circulating free fatty acids did not change, triglycerides and total cholesterol ( Figure 2H ) increased in plasma by 25.9±12.7% (triglycerides; P=0.002; n=8 per group) and 32.0±10.3% (cholesterol; P=0.04; n=8 per group; Figure 2I ). Liver sections of CD40 −/− mice showed signs of nonalcoholic steatohepatitis ( Figure 2J ). Notably, gene regulators of lipid metabolism such as carbohydrate-responsive element-binding protein (ChREBP) and acetyl-CoA-carboxylase 1 (ACC-1) increased in CD40 −/− liver tissue by 230.3±116.6% (ACC-1; P<0.0001; n=14 per group) and 688.2±286.2% (ChREBP; P<0.0001; n=14 per group; Figure 2K ).
CD40 Deficiency Promotes DIO and Its Metabolic Complications in Mice
CD40 Deficiency Potentiates Immune Cell Invasion and Inflammatory Gene Expression in VAT
In obesity, adipose cell size increases and inflammatory cells invade the adipose tissue. 8 The adipocyte cell size in CD40 −/− mice was significantly larger than in WT controls (350.1±104. 4 
CD40 on Lymphocytes, but Not on Adipocytes, Accounts for Its Proinflammatory Phenotype During DIO
A variety of cell types express CD40, including leukocytes and adipocytes. 14, 15 To decipher which cell type contributes to the phenotype observed in CD40-deficient animals, we isolated adipocytes from CD40 −/− and WT animals and quantified adipokine gene expression. Unexpectedly, CD40-deficient adipocytes expressed similar levels of TNFα Figure 4C ). In addition, Rag1/CD40 chimerism deteriorated glucose tolerance (n ≥5 per group; P=0.01 in repeated 2-way ANOVA) but not insulin tolerance (n ≥5 per group; P=0.1137 in repeated 2-way ANOVA; Figure 4D −/− mice consumed a high-fat diet (HFD) for 20 weeks. Relative increases in body weight (BW; percent increase from starting body weight) and total body fat, as assessed by magnetic resonance imaging-based body composition analysis, are shown for the indicated time points (A and B) . Weight of peripheral fat depositions is displayed as percent body weight (C). Leptin levels were determined by ELISA (D). Glucose tolerance testing (E) and insulin tolerance testing (F) were performed after intraperitoneal injection of glucose or insulin. Plasma glucose, cholesterol, free fatty acids (FAAs), and triglycerides were determined in animals fasting overnight (G and H). Liver cholesterol and triglycerides were quantified in whole-tissue lysates (H). Liver sections were stained with lipid-specific Oil Red O (I). mRNA of peroxisome proliferator-activated receptor-α (PPARα), carbohydrate-responsive element-binding protein (ChREBP), sterol regulatory element binding protein-1 (SREBP1c), free fatty acid synthase (FAS), acetyl-CoA-carboxylase 1 (ACC1), and apolipoprotein-B100 (ApoB100) was determined by real-time polymerase chain reaction in whole-liver tissue (J). Data are depicted as mean±SD. Statistical significance was calculated by repeated 2-way ANOVA (E and F) or unpaired 2-tailed Student t test between the indicated groups. *P<0.05.
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Activation of CD40 Signaling Protects Against Adipose Tissue Inflammation and Insulin Resistance
To test whether CD40 might be a therapeutic target in pre-established disease, 8-week-old WT mice consumed HFD for 6 weeks, followed by treatment with either the stimulating anti-CD40 antibody FGK45 21 Figure 5A ). Body fat deposition decreased after FGK45 treatment, as assessed by magnetic resonance imaging whole-body fat imaging ( Figure 4B) Figure 5F ). Relative numbers of proinflammatory M1-like CD11c + macrophages fell by 53±6.9% in FGK45-treated mice (n=11 per group; P=0.04; Figure 5F and 5G). Systemically, the numbers of circulating proinflammatory macrophages were reduced and levels of the Th2 cytokine IL-10 were increased after FGK45 treatment (Figure XIII in the online-only Data Supplement). These results indicate a protective role of CD40 in adipose tissue inflammation and its metabolic complications.
Activation of CD40 Signaling Dampens Proinflammatory Cytokine Expression in T Cells
Activation of T cells promotes adipose tissue inflammation and insulin resistance. 9, 10, 22 To explore whether CD40 participates in T-cell effector function, we stimulated splenocyte cultures with FGK45. Consistent with our findings in FGK45-treated mice, the numbers of CD4
+ , but not of CD8 + , T cells increased after anti-CD3/28 and FGK45 stimulation ( Figure 6A ), indicating that proliferation of protective T-cell subsets was promoted by CD40. Interestingly, stimulation of CD40 signaling prevented T-cell activation and the conversion 
CD40 Is Associated With Obesity in Humans
To test the relevance of our findings in humans, we quantified CD40 mRNA transcripts in lysates of subcutaneous adipose tissue. CD40 mRNA correlated with body mass index of donors (n=14; r=0.602, P=0.023; Figure 8A ). To attain further insight into whether CD40 expression is associated with components of the metabolic syndrome, we performed a pilot study measuring sCD40 in plasma of 183 patients with a high incidence of the metabolic syndrome (31.1%; Table I in the online-only Data Supplement). Notably, we detected higher levels of sCD40 in the plasma of obese individuals with a high body mass index (an increase of 19.1±96.3 ng/ml; n ≥32 per group; n=0.034; Figure 8B ) and high waist circumference (an increase of 20±23.1 ng/ml; n ≥80 per group; n=0.014; Figure 8C ). Notably, the association of higher sCD40 plasma levels in obese patients with a high waist circumference (Table  II in the online-only Data Supplement) was independent of age, sex, hypertension, glucose levels, and dyslipidemia in multivariate analysis (β=0.20, P=0.04; Figure 8B and 8C). In the tested cohort, sCD40 levels above the median were also independently associated with higher levels of the adipokine leptin (13.2±15 versus 19.3±20 ng/ml; β=0.02, P<0.01; Figure 8D ).
Discussion
Immune cell accumulation and expression of proinflammatory cytokines and chemokines characterize adipose tissue inflammation. 10 Current concepts attribute the regulation of adipose tissue inflammation to the composition of local immune cell subsets. Several reports have highlighted the potential contribution of specific antigen recognition by immune cells in adipose tissue inflammation. 5, 9, 10 The afferent limb of adaptive immunity requires costimulation in addition to antigens. Indeed, we and others previously demonstrated a requirement for the costimulatory molecules CD40L and 4-1BB to maintain adipose tissue inflammation in mice. 16, 23, 24 Surprisingly, Guo et al 18 previously suggested a protective role for the CD40 receptor in adipose tissue inflammation. In their study, CD40 −/− mice exhibited a hyperinflammatory phenotype with increased immune cell accumulation, elevated cytokine levels, hepatic steatosis, insulin resistance, and glucose intolerance. However, whether the observed phenotype depends on CD40 expressed in the vascular bed, as suggested in this study, or on leukocyte CD40 remains unclear. In our study, we confirmed the metabolic and hyperinflammatory phenotype of CD40 −/− mice and extended previous work by using various cell typespecific approaches, narrowing the phenotype of CD40 to a T cell-restricted effect. In line with this, CD40-deficient T cells conferred the hyperinflammatory phenotype to lymphocytefree Rag1 null mice, proposing a coinhibitory function of CD40 receptor on adipose tissue T cells that was responsive to pharmacological activation.
In light of the reported strong proinflammatory role of CD40 in inflammatory disease and immunity, 14, 25 it is striking that CD40 activation inhibited disease progression in a model of DIO. Although inflammation contributes to insulin resistance and obesity in mice and humans, the role of some key inflammatory molecules remains controversial. Schreyer et al 26 showed that at least 1 other member of the TNF receptor superfamily, Tnfrsf1a or Tnfrsf1b, figures importantly in protecting glucose homeostasis. Accordingly, genetic deletion of both receptors predisposed to DIO. 27 This finding is of particular interest because genetic deletion of the ligand TNFα protects against DIO. 28 Similarly, we showed that loss of CD40L protected against DIO, whereas genetic loss of its receptor aggravated metabolic disease. The diverse functions of CD40L can result from the engagement of different, functionally distinct receptors. Concordant with this concept, we previously reported that CD40L promotes atherogenesis, 29 whereas lack of CD40 does not affect this disease. During atherogenesis, CD40L bypasses interaction with CD40 and exerts its atherogenic actions by binding the leukocyte integrin Mac-1. 30 In our study, loss-and gain-of function experiments support the involvement of CD40 in T cells in adipose tissue inflammation. T cells increase in obese adipose tissue in mice and humans. 7, 9 There, Th cells exhibit predominantly markers of Th1-driven activated CD44 + CD62L
− effector-memory T cells. IFNγ secreted by these cells induces the expression of proinflammatory mediators such as IFN-inducible protein-10, MCP-1, and RANTES. IFNγ deficiency attenuated adipose tissue inflammation, emphasizing a proinflammatory role of Th1 CD4 + cells. 7 Additionally, CD8 + T cells directly promote monocyte differentiation and macrophage activation, as observed in later stages of obesity. 22 Our data show that stimulation of both CD4 + and CD8 + T cells with an agonistic CD40 antibody limits the production of the proinflammatory cytokines IFNγ and TNFα, favoring a protective phenotype in T cells and attenuating CD8 + effector function. In the classic concept of costimulation, CD40 ligation is required to efficiently activate B cells. However, CD40 has also been shown to provide costimulation to T cells, 31 promoting T-cell proliferation and attenuating proinflammatory cytokine release. 32, 33 In line with this concept, activation of CD40 on T cells has been shown to be part of a novel coinhibitory suppression loop by which CD40L-expressing cells such as B cells inhibited overactivation of T cells by abrogating proinflammatory cytokines and promoting protective signaling cascades. 33 Thus, the presence of CD40L-expressing cells such as B cells or T cells might be required to stimulate CD40 signaling and to activate this protective signaling cascade. We propose a model in which CD40 expression on both CD4 + and CD8 + cells is required to maintain a protective milieu in lean adipose. In obesity, CD40 expression in T cells decreases, and this downregulation might cause overactivation of T cells and fuel adipose tissue inflammation and its metabolic consequences. It is unresolved whether the decrease in CD40 in T and B cells is a result of an obesity-driven event or of more frequent CD40-CD40L interactions locally in VAT and subsequent shedding of CD40. 34 Furthermore, CD40 deficiency favored proinflammatory effector-memory T cells and diminished the T central memory and naïve T cells. Whether this was caused primarily by a defective central memory T cells generation as previously shown 35 needs to be explored in future experiments. Collectively, our data indicate that the expression of 18 proposed compensatory proliferation of T reg cells. It is also tempting to speculate whether enhanced recruitment of T cells into VAT proceeds by activation of the RANTES/CCR5 axis as our data suggest and as was previously confirmed in DIO. 36 Our experiments do not ultimately exclude the primary or indirect participation of CD40 expressed in cells other than T cells. Importantly, participation of 3 major CD40-expressing cell types, B cells, macrophages, and adipocytes, could be ruled out. First, the stimulation of B cells and macrophages with FGK45 increased cell activation and proinflammatory cytokine and chemokine secretion. Additionally, B-cell subsets and antibody production was not changed throughout our study. Second, CD40-deficient adipocytes showed impaired gene expression for MCP-1, thus not contributing to the proinflammatory phenotype in CD40 −/− mice. In addition, it may be possible that minor leukocyte subsets recently identified in VAT 10 but not quantified in our study such as neutrophils, eosinophils, mast cells, or natural killer cells contribute to the phenotype of CD40.
Despite the protective effect of CD40 on adipose tissue inflammation, its impact on obesity remains controversial. Although we show a clear effect on diet-induced weight gain in various models, a recent study reported hyperinflammation in fat but normal weight of CD40 −/− mice. 18 This is interesting because CD40 −/− mice fed LFD showed lower weight gain but similar patterns of basic energy metabolism compared with mice fed HFD. This raises the question of whether specific diet components might account for differential effects in the same knockout strain. Indeed, saturated lipid species were more frequent in the diet in our study and might be involved in dissociating obesity, insulin resistance, and inflammation, as recently suggested. 37 In addition, whether different genetic backgrounds of CD40
−/− animals frequently tested such as the C57Bl6/Ncr background in our study and the more obesityand insulin resistance-prone C57Bl/6J mice, 38 which served as control in our study, are a reason for the distinct inflammatory and metabolic phenotypes needs to be clarified. It is also challenging to explore how CD40 dissects increased hepatic steatosis from normal hepatic insulin resistance, but elevated expression of the transcription factor ChREBP may be a key as previously postulated. 39 Targeting CD40 has the potential of modulating various human diseases. Notably, CD40 stimulation can have protective actions in various experimental inflammatory diseases, including lupus and rheumatoid arthritis 21, 40 Activating anti-CD40 antibodies are currently under investigation in cancer, for the prevention of transplant rejection, and in autoimmune disease. 41 To investigate the relevance of our findings to humans, we measured plasma levels of sCD40, a shed product of membrane-bound CD40. Interestingly, we observed that sCD40 expression is associated with clinical obesity and plasma biomarkers of obesity such as leptin. These findings support a role for CD40 in human obesity. This finding raises the important question of whether sCD40 primarily serves as a marker for CD40 expression in activated cells or functions independently by clearing the CD40 ligands, as previously hypothesized for TNFα and TNF receptors. 42 This question is intriguing because ligation of CD40 limits its protein halflife on the cell surface and favors shedding of CD40 and thus accumulation of sCD40 in plasma. 34 However, further investigations are required to clarify the exact source and function of sCD40 in general and in obesity in particular. 
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CLINICAL PERSPECTIVE
Cardiovascular mortality caused by atherosclerosis, myocardial infarction, and stroke accounts for the majority of deaths worldwide. The metabolic syndrome, a cluster of cardiovascular risk factors including obesity, insulin resistance, hepatic steatosis, and dyslipidemia, is associated with chronic, low-grade inflammation in visceral adipose tissue. Notably, targeting adipose tissue inflammation can improve cardiovascular risk and outcome. However, the exact signaling pathways linking adipose tissue inflammation and cardiovascular disease, as ultimately required for establishing novel therapeutic strategies against cardiometabolic disease, remain poorly understood. Considerable evidence implicates the recruitment and activation of lymphocytes such as T cells in the regulation of adipose tissue inflammation. Modulation of anticipated proinflammatory pathways such as the CD40L/CD40 costimulatory dyad holds great promise in inflammation, but this concept has received scant attention in adipose tissue inflammation. In this study, we observed that mice deficient for CD40 exhibited dysmetabolism and increased adipose tissue inflammation. Conversely, activation of CD40 signaling by a stimulating antibody improved adipose tissue inflammation and dysmetabolism. Moreover, we found that elevated plasma levels of CD40 are associated with clinical obesity in humans. These findings support the functional involvement of CD40 in obesity. Targeting CD40 has the potential of modulating various human diseases, and stimulating anti-CD40 antibodies are currently under investigation in cancer, in the prevention of transplant rejection, and in autoimmune disease. Activation of the CD40 pathway with drugs already in clinical trials therefore might provide a novel, rapidly available therapeutic concept to combat cardiometabolic disease.
Bone marrow transplantation. Recipient mice were lethally irradiated with a single dose of 700cGy (Gammacell Exactor 40)
. Bone marrow of donor animals was filtered through a 100-mm cell strainer (BD Biosciences), centrifuged, resuspended, and injected at a concentration of 1x10 7 cells into the tail vein.
Adoptive transfer of T-cells. Splenic T-cells from WT or CD40
-/-mice were isolated by negative cell separation (Stem Cell Technologies, USA). Purity was > 95 % as assessed by flow cytometry. 5x10 6 cells in saline were transferred into Rag-1 -/-mice by intraperitoneal injection. Donor animals subsequently consumed HFD for 8 weeks. Re-population of donor animals was confirmed by detection of T-cells in flow cytometry.
Body composition analysis. Body composition, including total fat, lean mass, and water mass, was assessed by MRI-based body composition analysis (EchoMRI, Echo Medical Systems, USA) on a basis of four weekly follow-up measurements, or as indicated. Alternatively, MRI scans were used to image visceral fat depots.
Intraperitoneal glucose tolerance testing (GTT) and insulin tolerance testing (ITT).
Glucose and insulin tolerance testing were performed at the indicated time points. For glucose tolerance testing (GTT), mice were deprived of food 6 hours prior to the procedures and received intraperitoneal glucose injections (0.25-1 g/kg lean body mass, as assessed by body composition analysis). For insulin tolerance testing (ITT), mice were injected with human insulin intraperitoneally (0.1-0.5 U/kg, Actrapid Insulin, Novo Nordisk, Denmark). Blood samples were collected before and 15, 30, 45, 60, 90, and 120 minutes after the insulin or glucose injection. Plasma glucose concentration was measured with AccuChek GO (Roche Diagnostics, Switzerland). Insulin plasma levels were quantified at the indicated time points by ELISA (Mercodia, Sweden).
Euglycemic-hyperinsulinemic clamps (EHC).
After 20 weeks of diet, mice were subjected to euglycemic-hyperinsulinemic clamps. Four days prior to the clamping, mice were anesthetized and an indwelling catheter was placed into the right internal jugular vein. Mice were allowed to recover for 4 days after surgery, and body weight was monitored daily. On the day of the clamping, mice were deprived of food for 5 hours, followed by a continuous infusion of [3-3H] glucose (5 µCi bolus and 0.05 µCi/min) to measure basal glucose turnover.
After infusion of the tracer for 2 hours, EHC was performed. A continuous infusion of insulin (4 mU/kg/min) was initiated. Blood (5 µL) was sampled from the tail vein every 10 minutes to measure glucose levels. Euglycemia was maintained using a variable infusion of 30% glucose. To determine glucose specific activity, blood samples were taken regularly during the clamping. Metabolic caging. Animals were allowed to acclimatize to metabolic cages (Oxymax/CLAMS, Columbus Instruments, USA) for 24 hours prior to the observation period. Food intake, ambulatory movement, heat production, O 2 consumption, and CO 2 production were assessed and recorded during the 24-hour observation period.
Preparation of the stromal vascular fraction (SVF).
Murine epididymidal fat pads were minced and digested with collagenase for 30 minutes at 37°C (0.5 mg/ml, Collagenase B, Roche, Switzerland). Digested tissue was then filtered through a nylon mesh (100 µm). The stromal vascular fraction (SVF) and adipocyte fraction were obtained from the resulting pellet and supernatant, respectively.
Preparation of splenocytes.
Cells were released from spleen by nicking the capsule and gently rotating two microscope slides. Cell suspension was filtered through a nylon mesh (100 µm) and centrifuged.
Flow cytometry. The stromal vascular fraction (SVF) and splenocytes were obtained as described above. Remaining red blood cells were removed by incubation with a red blood cell lysing buffer (155mM NH 4 Cl, 5,7mM K 2 HPO 4 , 0,1mM EDTA, pH7,3). Cells were washed in PBS, and Fc-Receptors were blocked by anti-CD16/CD32 (eBioscience, USA) for 10 minutes on ice. Cells were then labeled with the indicated antibodies before quantification with a flow cytometer (BD FACS Canto II, BD Biosciences, USA). All antibodies were obtained from eBioscience, USA. Distinct leukocyte populations were identified upon cell surface expression of the indicated antigens: T-cells (CD3 + 
Isolation of total RNA and quantitative real-time PCR.
Organs were stored in RNAstabilizing reagent (RNAlater, Qiagen, USA) after final necropsy. RNA was extracted from epididymidal adipose tissue using TRIzol Reagent (Invitrogen, USA) and glycogen as a coprecipitator (Roche, Switzerland). Homogenization was performed using a rotor-stator dispergator (IKA, Germany). 1 µg of total RNA was transcribed into cDNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Switzerland). Subsequent quantitative real-time PCR was performed with a LightCycler 480 System with the LightCycler 480 SYBR Green I Master (Roche, Switzerland) detection format. Murine GAPDH served as control. Primer sequences are available upon request.
Quantification of CD40 expression. Visceral adipose tissue was digested with collagenase as described above. The stromal vascular fraction (SVF) and the floating adipocyte fraction were separated and total protein was isolated. Equal concentrations of protein were either loaded on Western blot and stained with a specific anti-CD40 antibody and visualized or CD40 concentrations were quantified by ELISA (R&D Systems, USA).
Microarray analysis of mRNA. RNA samples of wild-type and CD40-deficient mice were screened using a MicroRNA V2 Expression Profiling Kit and a MouseWG-6 v2 Expression BeadChip (Illumina, Inc., USA). Samples were then analyzed on iSCAN array scanner (Illumina Inc., USA). Analysis of murine plasma samples. Plasma levels of insulin, leptin, adiponectin, and FFAs were measured by ELISA, according to the manufacturers' protocols (Mercodia, Sweden; R&D Systems, USA; Cusabio, USA; Uscn Life Science Inc, China). Triglyceride, LDL, HDL, and total cholesterol levels of murine plasma samples were assessed by the COBAS Integra 400 plus system (Roche Diagnostics, Switzerland). Plasma cytokines were determined by cytometric bead arrays (CBA, BD Biosciences, USA), according to the manufacturer's protocol.
Histology and immunhistochemistry (IHC
Liver homogenisates. Liver samples were homogenized in 200µl PBS using a dispergator (IKA, Germany) and normalized to a protein concentration of 2.5 mg/ml. Lipids were extracted as previously described . Samples were analyzed by liquid chromatography-mass spectrometry on a 4000QTRAP™ LC/MS/MS system (Applied Biosystems, USA).
Measurement of antibody titers:
Plasma titers of antibodies were determined by chemiluminescent ELISA, as previously described .
Quantification of intracellular cytokines. Intracellular proteins were quantified by flow cytometry in splenocytes or cells of the stromal-vascular fraction. Cells were re-stimulated by phorbol-myristate-acetate (PMA, 81 nM), ionomycin (1.34 µM), brefeldin A (10 µM), or monensin (2 µM) in RPMI for 15 hours, or by cultivation on mouse anti-CD3 coated cell culture plates for the indicated time. Alternatively, specific leukocyte subsets were purified by magnetic bead positive isolation.
Clinical study population. In the observational study, a total of 183 patients visiting the Cardiovascular Risk Area of the University Clinic of Navarra (Spain) for a routine assessment were included in the study. Exclusion criteria included apparent atherosclerotic disease, based on absence of history of coronary disease, stroke, or peripheral artery disease, and a normal electrocardiogram; impaired renal or liver function, arteritis, and connective tissue diseases, inflammatory disease or cancer. Sample size was calculated according to the results of a previous study performed in our laboratory. Sample size was estimated using the programme EPIDAT vs. 3.1, to detect differences of 0.2 ng/ml in sCD40L, with a statistical power of 90%. The local committee on human research approved the study, which was performed in accordance with the Declaration of Helsinki, and all participants gave written informed consent. All participants underwent a complete medical examination, and anthropometric measurements were taken. Blood pressure was measured using a mercury sphygmomanometer in a sitting position. The average of two measurements was considered. Subjects were classified as obese and non-obese according to body-mass index (BMI) (obese ≥ 27.5 kg/m 2 ). High waist circumference was defined as >88 cm (women) and >102 cm (men). Serum and plasma were collected in Vacutainer tubes. Fasting serum glucose, cholesterol, triglycerides (TG), and high-density lipoprotein (HDL) cholesterol were measured by standard laboratory techniques. Plasma C-reactive protein levels (hsCRP) were measured by immunoturbidimetry in a Roche Modular analyzer. sCD40 in plasma was determined by ELISA (R&D Systems, USA). Subcutaneous fat tissue samples were obtained from ZenBio (USA).
Statistical analysis. Data analysis in the text section is presented as mean ± standard deviation (SD). Statistical testing employed Student's unpaired T-test between the groups as indicated. Significances in glucose tolerance (GTT) and insulin tolerance testing (ITT) were assessed by repeated two-way ANOVA between the treatment groups. In the clinical study, the normal distribution of variables was tested with the Shapiro-Wilk test. Differences across groups were compared by ANOVA, followed by the Bonferroni post-hoc test for normal variables and the Kruskal-Wallis test for non-normal variables. Spearman correlation coefficients for continuous variables were also used to assess univariate correlations. Pvalues <0.05 were considered statistically significant. Statistical analysis was performed with SPSS (SPSS, USA). Figure S1: CD40 deficiency alters the basic energy metabolism under diet-induced obesity (DIO). C57BL6 mice competent (WT) or deficient for CD40 (CD40 -/-) were fed a highfat diet (HFD) for 20 weeks. Ambulatory movement (A), heat production (expressed as kCal per hour, B), respiratory exchange ratio (RER, C) and food intake (D) were determined during a 24-hour observation period in metabolic cages after 20 weeks of diet. CaH and fat indicate carbohydrate and fat metabolism (C). Plasma levels of neuro-endocrine regulators of appetite, such as Neuropeptide Y, Agouti-related peptide (AgRP), and Ghrelin were quantified by ELISA in plasma samples of fasting animals after 20 weeks of diet (E). Data are presented as mean ± SD of at least 8 animals per group. Statistical significance was calculated by unpaired, two-tailed Student's T-Test between both groups. P-values are indicated in each graph. C57BL6 mice competent (WT) or deficient for CD40 (CD40 -/-) were fed a high-fat diet (HFD) or standard chow diet (LFD) for 12 weeks. Animals were non-fasting (A) or were fasted for 6 hours and subsequently glucose was injected intraperitoneally at a dose of 2g/kg body weight (B). Plasma samples were taken at 60 min after glucose injection and plasma insulin levels were quantified by ELISA. Data are presented as mean ± SD of at least 6 animals per group. Statistical significance was calculated by unpaired, two-tailed Student's T-Test between both groups; the p-value in indicated in the graph. Figure S5 . CD40 deficiency amplifies muscle insulin resistance in hyperinsulinemiceuglycemic clamps in vivo. C57BL6 mice competent (WT) or deficient for CD40 (CD40 -/-) were fed a standard diet (low-fat diet, LFD) or a high-fat diet (HFD) for 20 weeks. Hyperinsulinemic-euglycemic clamp analysis was performed by infused radioactively glucose (glucose infusion rate, GIR) to maintain euglycemic steady state under continuous insulin infusion. Rate of glucose disappearance was determined under basal (GDR) and insulin clamp conditions (Ins-GDR, A). Hepatic glucose production (HGP) and its suppression during insulin-clamp (% of basal HGP) was calculated (B). Glucose tracer uptake and mRNA expression of insulin receptor-1 (IRS-1) and glucose transporter-4 (GLUT-4) was quantified in muscle (C, D), and in different fat depots (E, F). SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; BAT, brown adipose tissue. Data are presented as mean ± SD of at least 8 animals per group. Statistical significance was calculated by unpaired, two-tailed Student's T-Test between both groups. P-values are indicated in each graph.
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T-cells
Regulatory T-cells Macrophages B-cells , and B2-cells (CD5 -CD23 + CD11b -CD19 + ) were identified in the peritoneal cavity (B, C). IgM-antibodies specific for the indicated epitopes were quantified in plasma samples. Data are presented as mean ± SD of at least 8 animals per group. Statistical significance was calculated by unpaired, two-tailed Student's T-Test between both groups; a p-value < 0.05 was considered significant (indicated by asterisk). Figure S13: Activation of CD40 receptor ameliorates metabolic parameters and inflammatory monocytosis during DIO. 8-week-old C57BL6 mice were fed a high-fat diet (HFD) for 6 weeks to induce the metabolic syndrome. Mice were subsequently divided in two groups and treated with the stimulating anti-CD40 antibody FGK45 or a corresponding isotype control (rat IgG2a) during an additional pair-feeding with HFD for 6 weeks. Insulin levels were quantified in plasma of fasting mice after 12-weeks of HFD consumption (A). Plasma levels of cholesterol, triglycerides, free fatty acids (FFAs), leptin, and adiponectin were determined after overnight starvation by ELISA (B). Absolute numbers of circulating leukocyte subsets (per µl blood) were quantified by flow cytometry (C), and demonstrated significant reduction of total monocytes (CD11b + CD115 + ), Gr-1 + inflammatory monocytes, and total B-cells (CD19 + ). T-helper cells were identified as CD4 + CD8 -, cytotoxic T-cells as CD4 -CD8 + cells. Plasma level of the Th2-cytokine IL-10 was quantified by cytometric bead assay (CBA, D). Data are presented as mean ± SD of 10 animals per group. Statistical significance was calculated by unpaired, two-tailed Student's T-Test at each time point between both groups; a p-value < 0.05 was considered significant (indicated by asterisk or by p-value in the graph). + dendritic cells/macrophages (A) and CD19 + B-cells (B) were isolated from visceral adipose tissue of HFD-consuming mice by bead isolation and stimulated with the CD40-activating antibody FGK45 or an according isotype antibody. After 24 hours of incubation, cell supernatant was screened for cytokine levels by cytometric bead assay (CBA). Cytokine levels are presented as % of IgG-stimulated concentration in the same animal. T-cells were isolated from 8-week old, male C57BL6 mice by bead separation. A purity of >90% T-cells was achieved. T-cells were subsequently stimulated by the agonistic antibody FGK45 or an according Isotype control (IgG) in vitro for 24 hours. T-cell specific activation was provided by anti-CD3 and anti-CD28 monoclonal antibodies. Expression of transcription factors GATA Binding Protein 3 (GATA3, C), T-box transcription factor TBX21 (T-bet, D), and forkhead box P3 (FoxP3, E) was quantified by intracellular FACS staining. Expression is expressed as mean fluorescence intensity (MFI) for each antibody binding. Data are presented as mean ± SD of at least 4 animals per group. Statistical significance was calculated by unpaired, two-tailed Student's T-Test at each time point between both groups; a p-value < 0.05 was considered significant as indicated in the graphs. + T-cells among splenocytes (C) were quantified by flow cytometry. Plasma levels of soluble metabolic markers, such as total cholesterol (Chol.), Triglycerides (Tri., D), free fatty acids (FFA, E), leptin (F), and adiponectin (G) were quantified in plasma samples of fasting mice. Data are presented as mean ± SD of at least 11 animals per group. Statistical significance was calculated by unpaired, two-tailed Student's T-Test between both groups as indicated in the graphs. + cells with coexpression of the dendritic cell marker CD11c. In the indicated, representative FACS plots Twere pre-gated on lymphocytes, macrophage-gates were excluded from lymphocytes, Bcells were gated in the whole leukocyte population in FSC/SSC-scatter plot. BMI, body-mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-c, high-density cholesterol; LDL-c, low-density cholesterol; TG, triglycerides; CRP, C-reactive protein. High waist circumference was defined as >88 cm (women) and >102 cm (men). Data are presented as mean ± standard deviation (SD).
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